Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

ESCAIDE participants are invited to the fifth Eurosurveillance scientific seminar on 30 November 2016

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Read our articles on mcr-1-mediated colistin resistance

Note of concern published for 'Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015',

In this issue

Home Eurosurveillance Weekly Release  2003: Volume 7/ Issue 17 Article 2
Back to Table of Contents

Eurosurveillance, Volume 7, Issue 17, 24 April 2003

Citation style for this article: Blommerde B. Netherlands to introduce routine HIV testing of pregnant women. Euro Surveill. 2003;7(17):pii=2215. Available online:

Netherlands to introduce routine HIV testing of pregnant women

Barbara Blommerde (, Public Health Department, Ministry of Health, the Netherlands.

Beginning in January 2004, screening tests for HIV are to be offered to all pregnant women in the Netherlands on an 'opt-out' basis to prevent transmission of HIV from mother to child.

Currently screening tests for hepatitis B and syphilis are offered to all pregnant women at about the 12th week of pregnancy. Frequently an HIV test is also offered at this time, but this is not standard practice at present.

The College of Healthcare Assurance in the Netherlands presented two options for HIV screening of pregnant women. The first was to offer a rapid 30 minute HIV test after obtaining informed consent in the standard way. The second was to offer a standard laboratory HIV test on an opt-out basis with the result becoming available after 7-10 days.

The midwife or obstetrician will routinely offer the HIV test together with other tests such as syphilis and hepatitis B. The pregnant woman can then refuse to have one or more of the offered tests. The State Secretary stressed the importance of good counselling, which includes providing information on the disadvantages as well as the advantages of a positive HIV test result. In this way women can make an informed choice whether or not to be tested.

The State Secretary chose the second option because it fits best with current screening test practice. Also the rapid 30 minute HIV test would produce a significant number of false positive test results in this low prevalence population, thus causing a lot of unnecessary concern.


back to top

Back to Table of Contents

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN 1560-7917] - ©2007-2016. All rights reserved.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.